Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs

Three Health Care-Focused SPACs Also Went Public

Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.

Finance Watch Public Company

Intracellular medicines pioneer Entrada Therapeutics, Inc., cancer drug developer Aura Biosciences, Inc. and dermatology-focused Biofrontera Inc. launched initial public offerings on 28 October, raising $275.1m combined and bringing the number of biopharmaceutical company IPOs in 2021 to 98.

The year is two offerings away from hitting the 100 IPO mark despite wild swings in biopharma company valuations in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business